Navigation Links
Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
Date:4/17/2012

WASHINGTON, D.C. Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA, a theme issue on comparative effectiveness research.

Deborah Schrag, M.D., M.P.H., of the Dana-Farber Cancer Institute, Boston, presented the findings of the study at a JAMA media briefing at the National Press Club.

"A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). However, longer survival was not observed in the subgroup of patients aged 65 years or older, " according to background information in the article. "Notwithstanding the uncertainty about benefits in the population aged 65 years or older, the Centers for Medicare & Medicaid Services (CMS) has covered bevacizumab therapy for its enrollees subsequent to Food and Drug Administration [FDA] approval. Little is known about how clinicians have interpreted efficacy studies to formulate treatment recommendations, and given that approximately two-thirds of patients with lung cancer receive their diagnoses at age 65 years or older, establishing the survival advantage of bevacizumab in the Medicare population is a priority for informed decision making."

Dr. Schrag and colleagues conducted a study to examine whether adding bevacizumab to carboplatin-paclitaxel was associated with improved survival in the Medicare population. The researchers used analytic strategies to address confounding (factors that can influence outcomes) and selection bias caused by the lack of treatment randomization in observational
'/>"/>

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-5665
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Kidney cancer patients do better when whole kidney is not removed, U-M study shows
2. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
3. Study examines medicare use for Mohs micrographic surgery and surgical excision for skin cancer
4. UT MD Anderson study finds cancer related pain often undertreated
5. Tattoos, Piercings Tied to Heavier Drinking in French Study
6. Surgery Rates Rising for Non-Melanoma Skin Cancer: Study
7. Dissolvable Heart Artery Stents Appear Safe in Study
8. Study identifies potential treatment for lethal childhood leukemia
9. Study recommends ways to evaluate end-of-life care in nursing homes
10. Mayo Clinic breast cancer study finds new type of mutation
11. Decision guide reduced uncertainty over breast cancer prevention, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... receiving record amounts of money for such efforts , ... for tobacco prevention programs by more than 15 percent ... amounts of money from tobacco taxes and from the ... , "Fully funded tobacco prevention and cessation programs stop ...
... , , LANGHORNE, Pa., ... revolutionized with the introduction of TendoFlex - an innovative, ... motion exercises and abdominal core strengthening, allowing users to ... and aching. TendoFlex lets users stretch ...
... , , , HARROGATE, England, Dec. 9 ... on Polyphenols and Health (ICPH) further demonstrates that Concord grape ... function in certain population groups. The Concord grape has long ... healthy aging, and researchers are now also seeking to understand ...
... , ATLANTA and ... medical transcription service provider in the U.S. and the only leading ... been rated No. 1 in their category for professional services in ... report. A first-time entrant into the annual survey, ...
... , WINNIPEG, Manitoba, Dec. 9 IBM ... with the Government of Manitoba to enhance healthcare throughout the ... system. This technology can offer healthcare providers secure and quick ... and quality of patient care while reducing healthcare costs. ...
... Department of Neurology at Jefferson Medical College (JMC) of Thomas ... the National Institutes of Health (NIH) for the creation of ... science research to its translation into clinical applications. The ... as much as $10 million by the end of award ...
Cached Medicine News:Health News:States Slash Funding for Tobacco Prevention Programs 2Health News:States Slash Funding for Tobacco Prevention Programs 3Health News:All-New TendoFlex(TM) Revolutionizes Stretching and Core Strengthening 2Health News:The Concord Grape Commands Attention at Major Scientific Conference 2Health News:The Concord Grape Commands Attention at Major Scientific Conference 3Health News:The Concord Grape Commands Attention at Major Scientific Conference 4Health News:The Concord Grape Commands Attention at Major Scientific Conference 5Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 2Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 3Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 2Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 3
(Date:3/27/2015)... , March 27, 2015   Hospira, Inc. ... in biosimilars and the world,s leading provider of ... that support an evaluation of biosimilarity of its ... and Drug Administration (FDA) conditionally approved name of ... (epoetin alfa). These study data were presented at ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Medicine Products: